Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study.
Jones RP, Sutton P, Greensmith RM, Santoyo-Castelazo A, Carr DF, Jenkins R, Rowe C, Hamlett J, Park BK, Terlizzo M, O'Grady E, Ghaneh P, Fenwick SW, Malik HZ, Poston GJ, Kitteringham NR.
Jones RP, et al.
Cancer Chemother Pharmacol. 2013 Aug;72(2):359-68. doi: 10.1007/s00280-013-2199-5. Epub 2013 Jun 12.
Cancer Chemother Pharmacol. 2013.
PMID: 23756919
Clinical Trial.